heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| Typical purity | ≥95% by HPLC | Research-grade material |
| Detection wavelength | 214 nm | Peptide bond absorbance |
| Reconstitution medium | Sterile water or saline | Prepare fresh or aliquot immediately |
| Storage (solution) | -80 °C, single-use aliquots | Avoid repeated freeze-thaw cycles |
| Common salt form | Acetate or trifluoroacetate | Affects mass and solubility |
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
=== World Health Organization === The World Health Organization has declared that finding where SARS-CoV-2 came from is a priority and that it is "essential for understanding how the pandemic started." In May 2020, the World Health Assembly, which governs the World Health Organization (WHO), passed a motion calling for a "comprehensive, independent and impartial" study into the COVID-19 pandemic. A record 137 countries, including China, co-sponsored the motion, giving overwhelming international endorsement to the study. In mid 2020, the World Health Organization (WHO) began negotiations with the government of China on conducting an official study into the origins of COVID-19. In November 2020, the WHO published a two-phase study plan. The purpose of the first phase was to better understand how the virus "might have started circulating in Wuhan", and a second phase involves longer-term studies based on the findings of the first phase. WHO director-general Tedros Adhanom said "We need to know the origin of this virus because it can help us to prevent future outbreaks," adding, "There is nothing to hide. We want to know the origin, and that's it." He also urged countries not to politicise the origin tracing process, saying that would only create barriers to learning the truth. In 2021, the World Health Assembly (on behalf of the WHO) commissioned a study conducted jointly between WHO experts and Chinese scientists. Echoing the assessment of most virologists, the study concluded that the virus most likely had a zoonotic origin in bats, possibly via an intermediate host.
The owners of the land where Lindow Man was found donated the body to the British Museum, and on 21 August it was transported to London. At the time, the body was dubbed "Pete Marsh" by Middlesex Hospital radiologists, a name subsequently adopted by local journalists, as was the similar "Pete Bogg". Lindow Man's official name is Lindow II, as there are other finds from the area: Lindow I (Lindow Woman) refers to a human skull, Lindow III to a "fragmented headless body", and Lindow IV to the upper thigh of an adult male, possibly that of Lindow Man. After the discovery of Lindow Man, there were no further archaeological excavations at Lindow Moss until 1987. A large piece of skin was found by workmen on the elevator on 6 February 1987. On this occasion, the police left the investigation to the archaeologists. Over 70 pieces were found, constituting Lindow III. Although the bone was not as well preserved as that of Lindow Man, the other tissues survived in better condition. The final discovery was that of Lindow IV on 14 June 1988. Part of a left leg and buttocks were found on the elevator, from a site just 15 metres (50 ft) west of where Lindow Man was found. Nearly three months later, on 12 September, a right thigh was discovered in the peat on the bucket of a digger. The proximity of the discovery sites, coupled with the fact that the remains were shown to come from an adult male, means that Lindow IV is probably part of Lindow Man.
Urey refused to be listed on the manuscript because he believed his status would cause others to underappreciate Miller's role in designing and conducting the experiment and so encouraged Miller to take full credit for the work. Despite this the set-up is still most commonly referred to including both their names. After not hearing from Science for a few weeks, a furious Urey wrote to the editorial board demanding an answer, stating, "If Science does not wish to publish this promptly we will send it to the Journal of the American Chemical Society." Miller's manuscript was eventually published in Science in May 1953.
The potato is really a healthy, easy and inexpensive food. The preparation of potatoes is pleasant and advantageous for the working class, as it requires almost no care and expense. The eagerness with which one sees children eating potatoes cooked under the ashes and finding themselves well, proves enough that they are suitable for all constitutions
== Management == Treatment depends on the underlying cause of the ketoacidosis. Diabetic ketoacidosis is resolved with insulin infusion, intravenous fluids, electrolyte replacement and supportive care. Alcoholic ketoacidosis is treated with intravenous dextrose and supportive care and usually does not require insulin. Starvation ketoacidosis can be resolved with intravenous dextrose with attention to electrolyte changes that can occur with refeeding syndrome.
Sources: en.wikipedia.org
Profilin is an actin-binding protein involved in the dynamic turnover and reconstruction of the actin cytoskeleton. It is found in most eukaryotic organisms. Profilin is important for spatially and temporally controlled growth of actin microfilaments, which is an essential process in cellular locomotion and cell shape changes. This restructuring of the actin cytoskeleton is essential for processes such as organ development, wound healing, and the hunting down of infectious intruders by cells of the immune system. Profilin also binds sequences rich in the amino acid proline in diverse proteins. While most profilin in the cell is bound to actin, profilins have over 50 different binding partners. Many of those are related to actin regulation, but profilin also seems to be involved in activities in the nucleus such as mRNA splicing. Profilin is the major allergen (via IgE) present in birch, grass, and other pollen.
=== Pharmacokinetics === Oral tacrolimus is slowly absorbed in the gastrointestinal tract, with a total bioavailability of 20 to 25% (but with variations from 5 to 67%) and highest blood plasma concentrations (Cmax) reached after one to three hours. Taking the drug together with a meal, especially one rich in fat, slows down resorption and reduces bioavailability. In the blood, tacrolimus is mainly bound to erythrocytes; only 5% are found in the plasma, of which more than 98.8% are bound to plasma proteins. The substance is metabolized in the liver, mainly via CYP3A, and in the intestinal wall. All metabolites found in the circulation are inactive. Biological half-life varies widely and seems to be higher for healthy persons (43 hours on average) than for patients with liver transplants (12 hours) or kidney transplants (16 hours), due to differences in clearance. Tacrolimus is predominantly eliminated via the faeces in form of its metabolites. When applied locally on eczema, tacrolimus has little to no bioavailability.
== Further reading == Arms, Thomas S. Encyclopedia of the Cold War (1994). Brune, Lester H. Chronology of the Cold War, 1917–1992 (Routledge, 2006) 720 pp of brief facts Hanes, Sharon M. and Richard C. Hanes. Cold War Almanac (2 vol 2003), 1460pp of brief facts Parrish, Thomas. The Cold War Encyclopedia (1996) Trahair, Richard C.S. and Robert Miller. Encyclopedia of Cold War Espionage, Spies, and Secret Operations (2012). excerpt Tucker, Spencer C. and Priscilla Mary Roberts, eds. The Encyclopedia of the Cold War: A Political, Social, and Military History (5 Vol., 2007). excerpt van Dijk, Ruud, ed. Encyclopedia of the Cold War (2 vol. 2017) excerpt
All three polymorphs crystallize simultaneously from aqueous solutions under ambient conditions. In additive-free aqueous solutions, calcite forms easily as the major product, while aragonite appears only as a minor product. At high saturation, vaterite is typically the first phase precipitated, which is followed by a transformation of the vaterite to calcite. This behavior seems to follow Ostwald's rule, in which the least stable polymorph crystallizes first, followed by the crystallization of different polymorphs via a sequence of increasingly stable phases. However, aragonite, whose stability lies between those of vaterite and calcite, seems to be the exception to this rule, as aragonite does not form as a precursor to calcite under ambient conditions.
The training and career pathways for internists vary considerably across different countries. Many programs require previous undergraduate education prior to medical school admission. This "pre-medical" education is typically four or five years in length. Graduate medical education programs vary in length by country. Medical education programs are tertiary-level courses, undertaken at a medical school attached to a university. In the US, medical school consists of four years. Hence, gaining a basic medical education may typically take eight years, depending on jurisdiction and university. Following completion of entry-level training, newly graduated medical practitioners are often required to undertake a period of supervised practice before their licensure, or registration, is granted, typically one or two years. This period may be referred to as "internship", "conditional registration", or "foundation programme". Then, doctors may follow specialty training in internal medicine if they wish, typically being selected to training programs through competition. In North America, this period of postgraduate training is referred to as residency training, followed by an optional fellowship if the internist decides to train in a subspecialty. In most countries, residency training for internal medicine lasts three years and centers on secondary and tertiary levels of health care, as opposed to primary health care. In Commonwealth countries, trainees are often called senior house officers for four years after the completion of their medical degree (foundation and core years).
Sources: en.wikipedia.org
Solid peptide is best kept frozen at about minus 20 degrees Celsius in a sealed container with desiccant. It should be allowed to reach room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is discouraged.
Reversed-phase liquid chromatography establishes purity, while mass spectrometry confirms molecular mass. The two techniques are normally used together. Retention time alone is not sufficient evidence of identity.
Different counterions change the mass per unit of peptide and can shift chromatographic behavior. Two samples of equal stated purity may therefore not be directly comparable. Reports should specify the counterion whenever quantitative comparisons are made.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.